Opinion on Pharmaceuticals in North America

Published within

« | ... | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Transition Therapeutics: showing potential in hepatitis

Toronto-based Transition Therapeutics has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. However, although its results to date look promising, the drug candidate looks set to face stiff competition from other pipeline products, several of which appear to have a head-start.

Published By Datamonitor
08 Aug 2006
CommentWire
CommentWire

UCB: allergy medication reveals increased sales

UCB's [UCB.BR] Zyrtec (cetrizine) sales are up 14% on the same quarter last year. The OTC and off-patent status of the leading antihistamine Claritin (loratadine) at the end of 2002 was expected to severely damage its competitor's sales. However, patients have instead rejected switching to readily available generic versions and have boosted prescription sales of Zyrtec.

Published By Datamonitor
26 Jan 2004
CommentWire
CommentWire

UCB: Cimzia's indication expansion hindered by FDA

Although the FDA's complete response letter for Cimzia in rheumatoid arthritis will delay its US approval, Datamonitor believes UCB has the experience to handle the setback and the drug may still reach the market by the second half of 2009. Ultimately however, the delay will not be a major impediment as extensive uptake is not expected at launch due to poor differentiation in a mature drug class.

Published By Datamonitor
07 Jan 2009
CommentWire
CommentWire

UCB: Vimpat's efficacy in epilepsy confirmed, but other indications offer more commercial potential

New pooled data confirm Vimpat's efficacy in the adjunctive treatment of uncontrolled partial-onset seizures in adults. The drug represents a new treatment option for patients with uncontrolled epilepsy, but its inferior efficacy to Keppra is expected to limit its uptake. Nevertheless, future indication expansions in migraine and fibromyalgia may expand Vimpat's commercial potential.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

Ulcer drugs: challenges in store

Procter & Gamble's [PG] launch of Prilosec OTC will have wide-ranging effects on the market for heartburn and ulcer drugs. The availability of an OTC alternative is leading US insurance companies to restrict access to competing prescription drugs. Although generic OTC omeprazole will not be available for several years, PPI companies must find successor products to protect their franchises.

Published By Datamonitor
22 Sep 2003
CommentWire
CommentWire

Ulcer drugs: generic launches threaten branded market

Novartis [NVS] has joined Mylan [MYL] and Schwarz [SRZG.F] in offering a generic version of blockbuster ulcer drug Prilosec in the US. The arrival of Novartis may open the floodgates for multiple generics in the ulcer drug market. Yet for companies launching generics before legal issues are settled, the risks are huge.

Published By Datamonitor
27 Aug 2003
Expert View
Expert View

Underwhelming data at IEC detract from perampanel's innovative mechanism

Eisai has presented positive data from the latest Phase III clinical trial of its novel anti-epileptic drug perampanel. Despite mixed Phase III data suggesting lower efficacy to perampanel's closest competitor, Trobalt/Potiga, Datamonitor recognizes potential for the novel AMPA receptor antagonist in the treatment of patients with drug-resistant epilepsy.

Published By Datamonitor
31 Aug 2011
Expert View
Expert View

US and EU regulators close in on pharmaceutical pay-for-delay deals

The evolving relationship between branded and generics pharmaceutical companies is set to undergo considerable change as regulators in both the US and EU move to restrict 'pay-for-delay' deals in a bid to increase generics cost-savings. As deals that delay the market entry of generics come under increasing scrutiny, the industry may find that its best option is to cease such practices altogether.

Published By Datamonitor
13 Jan 2010
CommentWire
CommentWire

US cholesterol: generics to benefit most from guidelines

Published By Datamonitor
16 May 2001
Expert View
Expert View

US healthcare reform: a double-edged sword

The US House of Representatives has passed legislation paving the way for major healthcare system reform designed to substantially decrease the number of individuals without health insurance. Despite its potential benefits, Datamonitor believes that the reform is a mixed blessing for the pharmaceutical industry as cost-containment pressures are set to intensify in the long term.

Published By Datamonitor
23 Mar 2010

« | ... | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | » »|

No help is available.